Your session is about to expire
← Back to Search
Chemotherapy
Onvansertib + FOLFIRI + Bevacizumab for Colorectal Cancer
Phase 1 & 2
Waitlist Available
Research Sponsored by Cardiff Oncology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to 28 days after last dose of study drug (up to 30 months)
Awards & highlights
Study Summary
This trial is testing a new cancer drug to see if it is safe and effective when used with other drugs to treat metastatic colorectal cancer.
Eligible Conditions
- Metastatic Colorectal Cancer
- KRAS Mutation
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline up to 28 days after last dose of study drug (up to 30 months)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to 28 days after last dose of study drug (up to 30 months)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Phase 1: Determine the Maximum Tolerated Dose (MTD)
Phase 1: Number of Participants With Adverse Events (AEs)
Phase 1: Number of Participants With Change from Baseline in Eastern Co-operative Oncology Group (ECOG) Performance Status
+6 moreSecondary outcome measures
Phase 2: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Onvansertib
Phase 2: Area Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Onvansertib
Phase 2: Disease Control Rate (DCR)
+7 moreSide effects data
From 2021 Phase 1 & 2 trial • 72 Patients • NCT0330333938%
Febrile neutropenia
31%
Hypokalaemia
28%
Diarrhoea
28%
Stomatitis
25%
Fatigue
22%
Nausea
22%
Epistaxis
19%
Oedema peripheral
19%
Platelet count decreased
19%
Alopecia
16%
Hypophosphataemia
16%
Acute myeloid leukaemia
16%
Sepsis
16%
Dyspnoea
16%
Cough
16%
Hypoalbuminaemia
13%
Hypoxia
13%
Lung infection
13%
Anaemia
13%
Rash maculo-papular
13%
Rash
13%
Hypocalcaemia
13%
Arthralgia
13%
Hypertension
13%
Hypotension
9%
Electrocardiogram QT prolonged
9%
Syncope
9%
Pneumonia
9%
Cellulitis
9%
Headache
9%
Abdominal pain upper
9%
Oral pain
9%
Staphylococcal infection
9%
Urinary tract infection
9%
Hypomagnesaemia
9%
Dizziness
9%
Oropharyngeal pain
9%
Petechiae
9%
Decreased appetite
9%
Alanine aminotransferase increased
9%
Abdominal pain
9%
Escherichia bacteraemia
9%
Blood creatine increased
9%
Mucosal inflammation
9%
Hyperbilirubinaemia
9%
Pleural effusion
9%
Vomiting
6%
Dry mouth
6%
Ear pain
6%
Lower gastrointestinal haemorrhage
6%
Fluid overload
6%
Dry skin
6%
Oral candidiasis
6%
Neuropathy peripheral
6%
Fall
6%
Pyrexia
6%
Nasal congestion
6%
Ecchymosis
6%
Blood alkaline phosphatase
6%
Insomnia
6%
Pain in extremity
6%
Haematemesis
6%
Odynophagia
6%
Proctalgia
6%
Staphylococcal bacteraemia
6%
Bacteraemia
6%
Pneumonia fungal
6%
Pruritus
6%
Dermatitis contact
6%
Purpora
6%
Non-cardiac chest pain
6%
Hyperkalaemia
6%
Hypercalcaemia
6%
Flank pain
6%
Aspartate aminotransferase increased
6%
Neutrophil count decreased
6%
Blood bilirubin increased
6%
Pleuritic pain
6%
Haematoma
6%
Conjunctival haemorrhage
3%
Back pain
3%
Atrial fibrillation
3%
Myalgia
3%
Hyperglycaemia
3%
Tumour lysis syndrome
3%
Mallory-Weiss syndrome
3%
Upper gastrointestinal haemorrhage
3%
Pain
3%
Respiratory failure
3%
Rash pruritic
3%
Musculoskeletal pain
3%
Face oedema
3%
Hyponatraemia
3%
Contusion
3%
Septic shock
3%
Candida infection
3%
Granulicatella bacteraemia
3%
Kidney infection
3%
Pancytopenia
3%
Colitis
3%
Melaena
3%
Constipation
3%
Transfusion reaction
3%
Dysgeusia
3%
Dyspnoea exertional
3%
Wheezing
3%
Neutropenia
3%
Weight decreased
3%
Anxiety
3%
Eye pruritus
3%
White blood cell count decreased
3%
Neutropenic colitis
3%
Mental status changes
3%
Chills
3%
Sinus tachycardia
3%
Haemoptysis
3%
Aphasia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Phase 2: Onvansertib 60 mg/m^2 + Decitabine
Phase 1b: Onvansertib 90 mg/m^2 + Decitabine
Phase 1b: Onvansertib 12 mg/m^2 + Low-dose Cytarabine
Phase 1b: Onvansertib 18 mg/m^2 + Low-dose Cytarabine
Phase 1b: Onvansertib 40 mg/m^2 + Low-dose Cytarabine
Phase 1b: Onvansertib 60 mg/m^2 + Low-dose Cytarabine
Phase 1b: Onvansertib 12 mg/m^2 + Decitabine
Phase 1b: Onvansertib 40 mg/m^2 + Decitabine
Phase 1b: Onvansertib 60 mg/m^2 + Decitabine
Phase 1b: Onvansertib 27 mg/m^2 + Low-dose Cytarabine
Phase 1b: Onvansertib 18 mg/m^2 + Decitabine
Phase 1b: Onvansertib 27 mg/m^2 + Decitabine
Trial Design
1Treatment groups
Experimental Treatment
Group I: Onvansertib + FOLFIRI + BevacizumabExperimental Treatment3 Interventions
Phase 1b: Onvansertib escalating starting dose of 12 mg/m^2 orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combination with FOLFIRI (180 mg/m^2 irinotecan, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU + 5 mg/kg bevacizumab. This Phase 1b portion of the study has been completed.
Phase 2: Onvansertib Recommended Phase 2 Dose (RP2D) of 15 mg/m^2 orally Day 1 through Day 5 and Day 15 through Day 19 of every 28-day cycle in combination with FOLFIRI (180 mg/m^2 irinotecan, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU + 5 mg/kg bevacizumab, with treatment modifications or delays based on unresolved toxicity experienced during a previous cycle.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Onvansertib
2017
Completed Phase 2
~220
FOLFIRI
2005
Completed Phase 3
~5860
Bevacizumab
2013
Completed Phase 4
~5280
Find a Location
Who is running the clinical trial?
Cardiff OncologyLead Sponsor
10 Previous Clinical Trials
551 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are 18 years old or older.You have agreed to participate in the study and have signed a document saying so.You are not currently receiving any other cancer treatments except for non-interventional surveys or observational studies.You have had cancer in the past, except for certain types.You have a medical condition that could make it unsafe for you to take the study drug, or that could make it difficult for you to receive treatment.Your organs must be functioning properly.You have an ongoing illness that is not being properly managed.You have a noticeable buildup of fluid in your abdomen or lungs.You have already received and did not respond well to the chemotherapy drugs fluoropyrimidine and oxaliplatin, with or without bevacizumab, or you experienced side effects that made it hard to continue the treatment.You cannot or do not want to swallow the study medication.You have advanced colorectal cancer that cannot be removed by surgery.You have a specific mutation in your Kras gene that has been confirmed by a certified laboratory. If you have a mutation in both Kras and BRAF-V600 genes or Microsatellite Instability High/Deficient Mismatch Repair (MSI-H/ddMMR), you cannot participate in this study.Your tumor tissue must be available for testing. If there is no existing sample, you will need to have a biopsy taken during screening.You should be able to perform your daily activities without much difficulty.You have received treatment for your cancer within the past 6 months, but you cannot have any treatment for 4 weeks before starting this study.You must have received chemotherapy treatment that includes a drug called oxaliplatin, with or without bevacizumab, for at least 6 weeks. If you received maintenance therapy with fluoropyrimidines, you may still be eligible with or without re-challenge with oxaliplatin in combination with fluoropyrimidines.If you have rectal cancer, receiving both pre-treatment and post-treatment will be considered as one treatment for advanced cancer.If you had to stop your first treatment because of side effects, you can still participate as long as your disease got worse less than 6 months after stopping that treatment.
Research Study Groups:
This trial has the following groups:- Group 1: Onvansertib + FOLFIRI + Bevacizumab
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is this medical research currently recruiting participants?
"At this time, the trial is not currently enrolling participants. It was initially published on May 6th 2019 and most recently amended on November 10th 2022. However, there are plenty of other options available; 882 trials for metastatic colorectal cancer (CRC) patients need help and 792 studies require individuals taking Onvansertib to join them in the research effort."
Answered by AI
What is the size of the participant pool for this experiment?
"Unfortunately, this experiment is not currently accepting participants. It was first listed on May 6th 2019 and the record was most recently amended November 10th 2022. If you seek other research opportunities related to metastatic colorectal cancer (crc), there are 882 studies that may be suitable for your needs; Additionally 792 trials require volunteers for their Onvansertib clinical trial."
Answered by AI
How many locations are included in the scope of this clinical trial?
"7 clinical sites are presently enrolling participants for this trial. Patients can choose from Rochester, Los Angeles, Phoenix and 4 other locations to minimize travel demands when participating in the study."
Answered by AI
What pathologies does Onvansertib have a proven efficacy against?
"Onvansertib is a viable therapeutic option for patients suffering from rectal carcinoma, colorectal carcinoma and sarcoma."
Answered by AI
Could you elucidate which other experiments have utilized Onvansertib?
"Currently, there are 212 studies investigating Onvansertib in Phase 3 with a total of 792 live trials. Most have been launched from Shanghai but trials can be found at 37411 medical locations world-wide."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger